Incidental use of ecstasy: no evidence for harmful effects on cognitive brain function in a prospective fMRI study by unknown
ORIGINAL INVESTIGATION
Incidental use of ecstasy: no evidence for harmful effects
on cognitive brain function in a prospective fMRI study
Gerry Jager & Maartje M. de Win & Hylke K. Vervaeke &
Thelma Schilt & Rene S. Kahn & Wim van den Brink &
Jan M. van Ree & Nick F. Ramsey
Received: 4 October 2006 /Accepted: 21 March 2007 /Published online: 3 May 2007
# Springer-Verlag 2007
Abstract
Rationale Heavy ecstasy use in humans has been associat-
ed with cognitive impairments and changes in cognitive
brain function supposedly due to damage to the serotonin
system. There is concern that even a single dose of 3,4-
methylenedioxymethamphetamine may be neurotoxic, but
very little is known about the consequences of a low dose
of ecstasy for cognitive brain function.
Objectives The objective of the study was to assess the
effects of a low dose of ecstasy on human cognitive brain
function using functional magnetic resonance imaging (fMRI).
Materials and method We prospectively studied, as part of
the NeXT (Netherlands XTC toxicity) study, sustained effects
of a low dose of ecstasy on brain function in 25 subjects before
and after their first episode of ecstasy use (mean 2.0±1.4
ecstasy pills, on average 11.1±12.9 weeks since last ecstasy
use), compared to 24 persistent ecstasy-naive controls, also
measured twice and matched with the novice users on age,
gender, IQ, and cannabis use. Cognitive brain function was
measured in the domains of working memory, selective
attention, and associative memory using fMRI.
Results No significant effects were found of a low dose of
ecstasy on working memory, selective attention, or asso-
ciative memory neither at the behavioral level nor at the
neurophysiological level.
Conclusions This study yielded no firm evidence for
sustained effects of a low dose of ecstasy on human
cognitive brain function. The present findings are relevant
for the development of prevention and harm reduction
strategies. Furthermore, the study is relevant to the
discussion concerning potential therapeutic use of ecstasy.
Keywords Ecstasy .MDMA . Prospective .




Department of Psychiatry, A.01.126,
Rudolf Magnus Institute of Neuroscience,
University Medical Center Utrecht,
Heidelberglaan 100,
3584 CX Utrecht, The Netherlands
M. M. de Win
Department of Radiology,
University of Amsterdam,
Academic Medical Center Amsterdam,
Amsterdam, The Netherlands
H. K. Vervaeke




Department of Psychiatry, University of Amsterdam,
Academic Medical Center Amsterdam,
Amsterdam, The Netherlands
W. van den Brink
Amsterdam Institute for Addiction Research and Department
of Psychiatry, University of Amsterdam,
Academic Medical Center,
Amsterdam, The Netherlands
J. M. van Ree
Department of Pharmacology and Anatomy, Rudolf Magnus
Institute of Neuroscience, University Medical Center,
Utrecht, The Netherlands
N. F. Ramsey
Department of Neurosurgery, Rudolf Magnus Institute
of Neuroscience, University Medical Center Utrecht,
Utrecht, The Netherlands
G. Jager (*)
Department of Neurosurgery, A.01.126, Rudolf Magnus Institute
of Neuroscience, University Medical Center Utrecht,
Heidelberglaan 100,
3584 CX Utrecht, The Netherlands
e-mail: gjager@umcutrecht.nl
Introduction
Ecstasy (3,4-methylenedioxymethamphetamine or MDMA)
is a popular recreational drug. A large body of evidence
indicates that MDMA has the potential to damage brain
serotonin neurons in various animal species (Easton and
Marsden 2006; Green et al. 2003). There is still controver-
sy, however, whether similar serotonergic damage does
occur in human ecstasy users (Gouzoulis-Mayfrank and
Daumann 2006; Kish 2002). Nonetheless, ecstasy use has
been frequently associated with a variety of functional
sequelae, including psychological problems and cognitive
impairments (Cole and Sumnall 2003; Parrott 2001).
Functional neuroimaging studies in ecstasy users have
reported changes in cognitive brain function as well. Both
decreased and enhanced brain activity related to memory
function has been observed in various brain regions,
including frontal, temporal, visual, and limbic areas
(Daumann et al. 2003, 2004, 2005; Moeller et al. 2004).
However, some important questions remain unanswered.
For one, most studies concern heavy ecstasy users, but
there is concern that even a single dose of MDMA might be
neurotoxic (Gijsman et al. 1999; McCann and Ricaurte
2001). For example, animal studies indicate that even after
a single dose of MDMA, damage can occur in the serotonin
system (Adori et al. 2006; O’Shea et al. 1998; Ricaurte et
al. 1988). However, whether these animal findings can be
extrapolated to humans is still debated (Easton and
Marsden 2006). Second, interpretation of human data is
hampered by the lack of baseline data (Gouzoulis-Mayfrank
and Daumann 2006). Only a few prospective studies have
been performed in ecstasy-naive volunteers, but these
studies invariably focused on acute instead of sustained or
long-term effects of ecstasy (Dumont and Verkes 2006).
There are compelling reasons why more research is needed
on the sustained effects of low dose ecstasy use in humans.
First, the majority of recreational ecstasy users are
incidental or moderate users (Rodgers et al. 2003; Scholey
et al. 2004). Second, interest is growing in the possible
beneficial actions of MDMA in posttraumatic stress
disorder and in late stage cancer to reduce anxiety and
agitation (MAPS Research Information1). Ideally, only a
longitudinal prospective study in ecstasy-naive subjects
randomly assigned to MDMA or placebo and conducted in
a laboratory setting could answer the question whether
ecstasy is neurotoxic in humans. However, given the
potential neurotoxicity of MDMA, such a study is ethically
not acceptable. Recently, it has been advocated to start
longitudinal prospective studies in specific groups of young
people who are at an increased risk for use of ecstasy
(Gouzoulis-Mayfrank and Daumann 2006). The current
study is the first that succeeded in this approach. We
investigated the effects of initial use of ecstasy on working
memory, selective attention and associative memory,
measured with functional magnetic resonance imaging
(fMRI), using a prospective naturalistic design. Based on
previous results with exactly the same fMRI task paradigms in
heavy poly-substance ecstasy users which indicated poorer
associative memory performance and altered brain activity in
associative memory-related regions (Jager et al. 2007b), we
hypothesized that first use of ecstasy would affect associative
memory in terms of performance and of brain function, but
not working memory and selective attention.
Materials and methods
This study is part of the Netherlands XTC Toxicity (NeXT)
Study. A detailed description of the design and objectives
of the NeXT study is provided in a paper on the methods
(De Win et al. 2005). Besides fMRI, subjects underwent
SPECT, MR imaging, and cognitive testing; results of these
measurements are or will be reported in separate publica-
tions (De Win et al. 2007; Schilt et al. 2007).
Subjects
Between April 2002 and April 2004, a total of 188 young
adults (18–35 years) were included in the prospective
cohort study of the NeXT project. Of this cohort, 96
participated in the present fMRI study. At the time of
inclusion, none of the subjects had ever used ecstasy, but
they were selected for being at high risk of initiating the use
of ecstasy in the near future (see below). Subject recruit-
ment consisted of a combination of targeted site sampling,
advertisement2, and snowball sampling referrals. For details
on recruitment, inclusion and exclusion criteria, we refer to
Vervaeke et al. (2006) and De Win et al. (2005). Main
inclusion criterion was a high probability to start using
ecstasy based on the intention to probably or certainly use
ecstasy for the first time in the near future and/or ecstasy
use by peers. All subjects were right-handed and were
excluded if they reported: major medical or psychiatric
disorders; current use of psychotropic medications; use of
intravenous drugs; pregnancy; and contraindications for
MRI. Except for smoking, which was allowed until 2 h
before scanning, subjects had to abstain from psychoactive
substances for at least 2 weeks and from alcohol for at least
1 week before testing. Compliance to abstinence was
1 MAPS Research Information at http://www.maps.org/mdma/ for
information on approved phase I and II studies.
2 Advertisements were placed on the internet, on a special website for
this study from the Academic Medical Center Amsterdam and by a
pop-up advertising campaign on the Microsoft MSN Network.
404 Psychopharmacology (2007) 193:403–414
checked by urine drug screening (enzyme-multiplied
immunoassay for amphetamines, ecstasy, opiates, cocaine,
benzodiazepines, cannabis, and alcohol).
Subjects were fully informed about the potential risk of
ecstasy use in the study information letter and gave their
written consent according to the Helsinki Declaration. The
local ethics committee approved the study. Subjects were
paid for their participation ( 150 Euro per session of 2 days).
Procedure
At baseline, all 96 subjects underwent fMRI scanning and
completed validated self-report questionnaires about their
drug use (Van de Wijngaart et al. 1997). They were
screened for axis I psychiatric disorders using the Dutch
version of the mini international neuropsychiatric interview
for DSM-IV clinical disorders (Sheehan et al. 1998). Urine
samples were collected, and pre-morbid verbal intelligence
was estimated using the Dutch version of the National
Adult Reading Test (Schmand et al. 1991). After baseline
examination, subjects were approached at regular intervals
to fill out a questionnaire concerning drug use (four in total
during a follow-up period of approximately 18 months).
Within this follow-up period, 27 subjects started to use
ecstasy. These subjects were invited for a second fMRI scan
relatively soon after their first ecstasy use and with a
maximum cumulative ecstasy dose of ten tablets. As a
consequence of the latter criterion, one subject who has
used 20 tablets had to be excluded from the current study,
leaving 26 novice ecstasy users for the analysis. The control
group, also scanned a second time, consisted of 24 subjects
selected from the initial baseline sample who did not use
ecstasy within the follow-up period, based on age, gender,
IQ, and history of cannabis use (for individual matching
with the users). Urine drug screening and drug use
questionnaires were repeated.
Assessment of working memory, selective attention,
and associative memory
Three fMRI tasks were administered: a working memory
task based on Sternberg’s item-recognition paradigm
(denoted STERN), a visuo-auditory selective attention task
(SAT), and a pictorial associative memory task (PMT) that
depends on (para)hippocampal brain function.
The STERN task involves memorizing sets of five letters
(the target set). After this, a series of ten letters is displayed
in sequence (Fig. 1). Subjects have to decide whether
subsequently presented letters belong to the set or not.
Before scanning, subjects practiced on a specific set of
letters for 21 min. During scanning, two experimental tasks
were administered, which differed only with regard to the
target set(s): a novel set and a practiced set. In the practiced
set task (PT), the specific set was used repeatedly. In the
novel set task (NT), the composition of the target set was
changed after every run of ten trials. In the scanner, both
tasks were presented in eight epochs of ten stimuli each. An
additional reaction time control task (CT) was included (also
eight epochs of ten stimuli), as well as eight rest periods of
equal epoch duration (for further details on the STERN, we
refer to Jansma et al. 2001, 2004, and Ramsey et al. 2004).
The SAT is an oddball detection task (Fig. 2) and
involves detection of deviant stimuli (either tones deviant in
pitch from a baseline tone or dots deviant in size from a
Fig. 1 The temporal sequence
of events is shown for the
STERN task. Each epoch starts
with presentation of the target
set and is followed by ten trials.
Subjects have to press a button
as fast as possible if the letter
belongs to the target set. Details
are described in “Materials and
methods”
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baseline dot). A threshold for detecting differences in pitch
and dot size was determined individually before the scan
session by adjusting it until the subject detected at least
80% of the deviant stimuli. Tones and dots were presented
simultaneously with a variable interstimulus interval (mean
1.0 s) and were presented in 16 epochs of 30 s each. At the
start of each epoch, subjects were instructed to attend either
to the tones while ignoring the dots (TO) or vice versa
(DO). Eight rest periods (RS) of equal epoch duration were
intermixed (for further details, we refer to Jager et al. 2006).
The PMT is a pictorial memory task modified from a
paradigm from Henke et al. (1997). It involves three
experimental tasks: (1) an associative learning task (AL)
where subjects have to encode an association between two
pictures; (2) a classification task in which single item
pictures have to be classified (SC); and (3) a retrieval task
(RE) where subjects have to recall specific picture pairs
previously presented during the associative learning task.
The RE task provides a performance measure. Figure 3
depicts a schematic example of the PMT task. Each picture
Fig. 2 The temporal sequence
of events for the SAT task. Each
epoch (duration 29 s) starts with
an instruction slide (5 s), indi-
cating ‘rest’, ‘attend to tones
only’, or ‘attend to dots only’.
Both during ‘tones only’ and
‘dots only’, the instruction slide
is followed by a series of 25
stimuli (simultaneous asynchro-
nous presentation of tones and
dots at a variable inter-stimulus
interval rate) of which, on aver-
age, 20% deviant (targets). In
case of a target, subjects have to
press a button as fast as possi-
ble. Before fMRI scanning, the
difference between standard and
deviant tones and dots is deter-
mined for each individual by
changing the contrast until a
performance of 80% correct is
obtained
Fig. 3 The temporal sequence
of events is shown for the PMT
task. Each epoch starts with an
instruction slide (5 s) followed
by a fixation cross (2.5 s). This
is followed by eight trials of
7.5 s each (picture pair 5 s,
fixation cross 2.5 s). Subjects
have to respond to the task by
pressing one out of two buttons
according to the instruction in
each task condition. Details are
described in “Materials and
methods”
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is presented for 5,000 ms, followed by a 2,340-ms fixation
cross. Each task is presented in four epochs (duration 65 s)
of eight stimuli. Also, four rest periods (RS) are included of
equal epoch duration. A fixed-order sequence, i.e., RS, AL,
SC, and RE, is repeated four times (for further details, we
refer to Jager et al. 2007a).
FMRI data acquisition
Scans were made on a Philips ACS-NT 1.5 Tesla MR-
scanner with PT 6,000 gradients using a standard scan
protocol (navigated 3D PRESTO; Ramsey et al. 1998). For
the STERN task, a single run of 384 scans was acquired
over a period of 18 min (scan parameters: TR 24.5 ms, TE
35.5 ms, flip angle 10.5°, FOV 208×256×120, matrix 52×
64×30, voxel size 4.0 mm isotropic, scan time 2,800 ms,
30 slices, transaxial orientation). Each epoch spanned 12
scans and lasted 33.6 s. This was followed by one volume
with a flip angle of 30° for registration purposes. For the
SAT task, a single run of 360 scans was acquired over a
period of 12 min. (scan parameters: TE 35.7 ms TR
23.7 ms, flip angle 10.5°, FOV 208×256×88, matrix 52×
64×22, voxel size 4.0 mm isotropic, time per scan
2,000 ms, 22 slices, transaxial orientation). Each epoch
spanned 15 scans and lasted 30 s. This was also followed
by one volume with a flip angle of 30° for registration
purposes. Then, to allow for some rest in between tasks, a
volumetric T1-weighted MR anatomical scan was acquired
for spatial localization. Acquisition parameters were FOV
256×256, TR 30 ms, TE 4.6 ms, matrix 128×128×150,
flip angle 30°, with 150 slices of 1.2-mm thickness. Finally,
for PMT, a single run of 432 scans was acquired over a
period of 18 min (scan parameters: TE 37 ms TR 24.4 ms,
flip angle 9°, FOV 208×256×104, matrix 52×64×26,
voxel size 4.0 mm isotropic, time per scan 2,340 ms, 26
slices, scan orientation parallel to the long axis of the
hippocampus). Each epoch spanned 27 scans and lasted
63 s. This was followed by one volume that was acquired
with a flip angle of 30° for registration purposes. Details on
the scan procedure and scan parameters for STERN, SAT,
and PMT have been previously described in Jansma et al.
(2001), Ramsey et al. (2004), and Jager et al. (2007a).
Data and data analysis
Demographic and drug use data
Various aspects of ecstasy use were assessed [frequency of
use, cumulative number of tablets, duration of use (months
between first and last ecstasy use) and abstinence (number
of weeks since last ecstasy use)]. Additional drug use data
included lifetime and last year use of cannabis (number of
joints), amphetamine and cocaine (number of occasions),
and last year alcohol and tobacco consumption (drinks per
week versus cigarettes per week). Demographic variables
included age, gender, and verbal IQ.
Performance data
Outcome measures included performance accuracy (error
rate for STERN, number correctly identified deviant stimuli
for SAT, and percentage correct responses during RE for
PMT) and reaction time (STERN only; measurements of
mean reaction time during CT, PT, and NT).
fMRI data
After reconstruction, functional and anatomical data were
processed off-line using PV-wave® and Matlab® processing
software. For all three tasks (STERN, SAT, and PMT),
preprocessing of the fMRI data included several steps.
First, after motion correction, individual statistical activity
maps were generated for each of the task conditions
compared to the rest condition by means of multiple
regression analysis (Worsley and Friston 1995). Next, these
maps were smoothed (FWHM 8 mm) and normalized into
standard MNI space (Collins et al. 1994). Then, to define
the regions of interest (ROIs) for each task, the smoothed
and normalized single-subject maps from the baseline
session (when all subjects were ecstasy-naive) were
combined into a group map, creating a contrast of interest
for each task and using z statistics (for details, see Jansma et
al. 2001). For all contrasts, the statistical threshold for
significant signal change was adjusted to yield separate
regions of interest (ROIs), but always met the p<0.05 level,
corrected for the total number of voxels in the brain. Using
higher thresholds was necessary because with the large
sample size (n=49), ROIs merge when using the p<0.05
threshold. For STERN, the contrast NT–CT eliminated
activity not directly involved in working memory and
yielded several working memory-specific ROIs at a
threshold of z=6.0 (p<0.01, corrected) with a cluster size
of at least 10 voxels. Using the same ROIs for all subjects,
mean activity values (i.e., the average z value of all voxels
within the ROI) were obtained for CT, PT, and NT. ROIs
were defined on the combined group map based on the
baseline scans of all subjects. The same ROIs were used in
the analyses of the fMRI data from the follow-up session
after meticulous co-registration of the normalized follow-up
functional scans onto the normalized baseline anatomy
scan.
Similarly, for SAT, ROIs were defined based on the TO-
RS contrast z=6.0 (p<0.01, corrected, clusters ≥10 voxels),
and mean activity values were obtained for TO and DO.
For PMT, the contrast AL-SC eliminated activity not
directly involved in associative learning and yielded several
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ROIs at a threshold of z=5.0 (p<0.01, corrected, clusters ≥10
voxels). For each of the ROIs, Δt variables were computed,
reflecting a measure for associative learning (contrasting AL
with SC) and one for retrieval (contrasting RE with SC). Δt
variables were entered into statistical analyses.
The size of the (para)hippocampal ROIs was large, with
activity extending into the fusiform gyrus. Because the
(para)hippocampal regions are critically involved in asso-
ciative memory processing, we added a second analysis to
improve specificity by limiting the analysis to anatomically
defined regions (right and left hippocampus, right and left
parahippocampal gyrus). For this purpose, a segmentation
procedure (Talairach and Tournoux 1988) was applied
based on individual anatomical scans, yielding four
separate clusters (right and left hippocampus, right and left
parahippocampal gyrus) marked for each subject separately
(for details, we refer to Jager et al. 2007a). Then, per
individual, two statistical activity contrast maps based on an
AL-SC and RE-SC contrast, respectively, z=3.0 (p<0.05
corrected) were generated. After this, mean activity values
within the four clusters for both contrast maps were
obtained for each subject. Additionally, a voxel-by-voxel
approach was applied within a confined search space, i.e., a
small volume template was constructed of the (para)
hippocampal region bilaterally (for details on this semi
automatic small volume correction method, we refer to
Matochik et al. 2003) in SPM2. Based on the smoothed
single subject contrast maps group contrast maps were con-
structed. After this, group differences were tested using an F
test with a family-wise error correction (FWE) at p<0.05.
ROIs for STERN, SAT, and PMT are listed in Table 2.
For each task and both scan sessions separately, mean
activity values and Δt variables were entered into GLM
repeated measures analyses.
To check for group differences in activation outside the
ROIs, the smoothed and normalized single subject maps
were also combined into a group contrast map (data not
shown) for each task, contrasting ecstasy-naive controls to
incident ecstasy users using a voxel-by-voxel approach and
z statistics (z=4.5, p<0.05 corrected). Both during baseline,
as well as during follow-up, the group contrast maps
yielded no significant (Z=4.5) differences in extent or
magnitude of brain activity between the groups. This
indicates that both novice ecstasy users and persistent
ecstasy-naive controls yielded highly similar patterns of
brain activity during baseline, and this was still the case
during follow-up.
Finally, we compared the results from the aforemen-
tioned approach, i.e., using t statistics in the first (fixed
effects) and z statistics in the second (random effects) stage
of fMRI analyses, with the commonly used random-effects
analysis for fMRI in SPM, i.e., entering first level
regression-coefficients (or betas) into the second level
random-effects group analysis. This yielded no significant
outcome differences. Therefore, these data are not reported.
Statistical analyses
One-incident ecstasy user was excluded based on a positive
urine test for cocaine, leaving 25 novice users for the
analysis. Incidental technical malfunction of the MR
scanner or the computer used for task presentation resulted
in some missing or incomplete data. As a consequence,
datasets were not complete for each of the included 49
subjects on each task paradigm, and results are reported for
each task separately with the number of subjects that were
included within brackets.
To test whether ecstasy users differed from ecstasy-naive
controls at baseline and at follow-up in terms of age, verbal
IQ and use of other substances than ecstasy (cannabis,
amphetamine, cocaine, tobacco, and alcohol), t tests and
non-parametric Kolmogorov–Smirnov tests were applied.
To assess effects of ecstasy on task performance
(accuracy, reaction times), GLM repeated measures analysis
was applied for each task separately, with group as fixed
factor and with session (baseline, follow-up) and task
condition as within-subject factors.
Effects of ecstasy on brain activity were also tested using
GLM repeated measures analysis, with brain activity as
dependent variable and session, task condition, and ROIs
(listed for all three tasks STERN, SAT, and PMT in Table 2)
as within-subject factors.
Dose-response measures were examined using correla-
tion analyses (Spearman’s rho) in the group of novice
ecstasy users with cumulative number of ecstasy tablets,
duration of use, and duration of abstinence as predictor
variables, and performance and brain activity as outcome
variables. All analyses were performed using SPSS version
12.0.1 (SPSS, Chicago, IL, USA).
Results
Sample characteristics and drug use data
Table 1 shows baseline and follow-up characteristics on
demographics and substance use of subjects that participat-
ed in the follow-up session. Incident ecstasy users used 2.0
tablets on average (range, 0.5–6, median 1.5 tablets) in a
mean period of 6.7 weeks (SD 9.4) during an average
follow-up period of 15.9 months (SD 4.6). The majority of
novice ecstasy users had used ecstasy only once (N=15/25;
60%). At baseline, the two groups of future ecstasy users
and persistent ecstasy-naive controls were similar in terms
of gender distribution, age (p=0.34), and verbal IQ (p=
0.93). Also, the two groups did not differ in terms of
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smoking, use of alcohol, cannabis, amphetamines, and
cocaine (all p values >0.50). With the exception of ecstasy
use, at follow-up, incident ecstasy users and controls were
still very similar in terms of age and use of other drugs (all
p values >0.40).
Performance data
Performance data are summarized in Fig. 4.
Working memory (N=44; 20 incident ecstasy users,
24 persistent ecstasy-naive controls)
Repeated measures analyses were performed on speed
and accuracy of task performance as dependent varia-
bles, group (novice users, controls) as fixed factor, and
session (baseline, follow-up) and task (CT, PT, and NT)
as within-subject factors. These analyses yielded no
significant group differences. Apart from a marginally
significant three-way interaction for reaction time, between
session, task and group (F(1,41)=2.65, p<0.10), all other
main or interaction effects of initial ecstasy use showed p
values >0.30.
Selective attention (N=43: 24 incident ecstasy users,
19 persistent ecstasy-naive controls)
Repeated measures analysis revealed no significant effects
of incident ecstasy use on threshold values for detecting
80% of the targets. Performance accuracy was similar for
both groups (all p values >0.20).
Associative memory (N=45; 24 incident ecstasy users,
21 persistent ecstasy-naive controls)
Repeated measures analysis with performance accuracy as
dependent variables, group as fixed factor, and session and
task (SC, RE) as within-subject factors revealed no
significant effects of group (p>0.25), indicating that simple
classification and recall accuracy were not affected by
incident ecstasy use.
Brain activity
For STERN (N=49), based on the NT–CT contrast, four
ROIs reached significance in the frontal, parietal, and the
fusiform gyrus. For SAT (N=47; 25 users, 22 controls),
based on the TO-RS contrast, six areas in the frontal,
auditory, and visual cortex were activated above threshold.
In addition, the TO-DO contrast yielded four areas in the
inferior frontal, visual, and auditory cortices where brain
activity was modulated by attention. Finally, for PMT
(N=49), the group contrast map (AL-SC) yielded nine
ROIs in the (para)hippocampal regions bilaterally, the
frontal and the occipital cortex. There was some overlap
in ROIs between tasks. The anterior cingulate cortex was
activated during all three tasks, whereas the right inferior
frontal gyrus and the left dorsolateral prefrontal cortex were
activated both during STERN and PMT. Table 2 shows
ROIs, their MNI coordinates (X, Y, Z), and peak activity
values for each task. GLM repeated measures analyses of
the fMRI signal in the ROIs were conducted for each task
separately.
Table 1 Demographics and characteristics of ecstasy use and use of other drugs (mean±SD)
Ecstasy users (N=25) Controls (N=24)
Baseline Follow-up Baseline Follow-up
Gender 9M, 16F 8M, 16F
Agea,b 21.8±2.5 22.8±2.7 21.2±1.8 23.0±1.9
DART-IQa,b 103.4±7.4 103.6±10.0
Ecstasy
Cumulative dose (tablets) 2.0±1.4
Time since last use (weeks) 11.1±12.9
Duration of use (months) 1.2±2.4
Other substances (last year)c,d
Alcohol (drinks/week) 8.9±7.2 9.1±7.6 8.9±7.0 7.2±5.5
Tobacco (cigarettes/week) 37.6±50.8 23.8±37.6 22.9±42.1 22.5±35.4
Cannabis (number of joints) 25.1±38.5 31.6±53.6 19.8±31.9 22.4±64.3
Amphetamine (number of occasions) 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0
Cocaine (number of occasions) 1.0±2.2 1.4±2.6 0.75±2.0 0.25±1.2
a Baseline novice users vs controls p<0.05 (t test)
b Follow-up novice users vs controls p<0.05 (t test)
c Baseline and follow-up, novice users vs controls p<0.05 (Kolmogorov–Smirnov Z)
d Novice users and controls, baseline vs follow-up p<0.05 (Kolmogorov–Smirnov Z). Except for ecstasy use, no significant differences were
found between groups or between sessions.
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Working memory-related brain activity (STERN)
Whole brain analysis Two contrasts were examined. First,
working memory activity (NT versus CT) was compared
between groups, with session and ROIs (Table 2) as
within-subject factors. There were no significant differ-
ences between groups (all p values >0.20), indicating that
incident ecstasy use did not affect patterns of brain activity
Fig. 4 Task performance on the STERN, SAT, and PMT during
baseline and follow-up for initial ecstasy users and persistent ecstasy-
naive controls. a Reaction time (milliseconds) for reaction time
control task (CT), the practiced task (PT), and the novel task (NT). b
Accuracy during SAT (number of correctly identified targets during
tone and dot detection). c Accuracy during PMT (percentage correct
answers) for the simple classification control task (SC) and the
recognition task (RE)
Table 2 Brain regions of interest engaged in STERN, SAT, and PMT, respectively
Task Region Brodmann area Number of voxels X Y Z Maximum z value
STERN l-SPC 7 213 30 −63 44 14.88
l-DLPFC 9/46 192 42 5 28 13.03
ACC 6/24 73 6 9 52 13.82
l-FuG 37 64 46 −63 −12 10.03
SAT r-IFG 47 224 −42 21 0 12.95
l-AUD 41/42/22 157 58 −23 8 13.97
ACC 8/24 130 −2 21 44 15.41
r-AUD 41/42/22 98 −58 −31 8 13.66
l-PcG 6 36 50 −3 44 9.94
l-INS 13 12 10 34 21 9.55
SAT-attentiona VIS 23 252 −10 −71 8 8.01
l-IFG 9/47 43 50 17 20 6.27
l-AUD 42 33 60 −31 8 5.51
r-AUD 42 23 −58 −27 0 6.13
PMT r-PHG 37/36 153 −26 −47 −12 13.05
l-PHG 37/36 134 26 −47 −12 12.29
l-DLPFC 9 116 46 13 28 11.89
l-MOG 19 98 34 −87 16 10.01
r-MOG 18 95 −34 −87 12 10.76
r-DLPFC 46 41 −50 29 20 7.37
ACC 8/24 34 2 25 44 6.91
r-IFG 47 27 −42 26 −8 6.62
l-IFG 47 22 50 21 −8 6.54
MNI coordinates are shown for the regions of interest involved in working memory (STERN), selective attention (SAT), and associative memory
(PMT). The coordinates X, Y, and Z represent location of the voxels with the highest z value in the group map. Corresponding names and
Brodmann areas are obtained from the location of voxels with the highest z value.
l- Left, r- right, SPC superior parietal cortex, DLPFC dorsolateral prefrontal cortex, ACC anterior cingulate cortex, FuG fusiform gyrus, IFG
inferior frontal gyrus, AUD auditory cortex, PcG precentral gyrus, INS insula, PHG parahippocampal gyrus, MOG middle occipital gyrus, VIS =
visual cortex
a Shows the MNI coordinates for the regions where activity is modulated through attention during SAT.
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in the engaged network. Next, the effect of practice (NT
versus PT, reflecting flexibility of the WM system; Jansma
et al. 2001) was compared. This also revealed no
significant differences between groups, indicating that
ecstasy did not affect the way practice reduces activity in
the WM network.
Selective attention-related brain activity (SAT)
Whole brain analysis Selective attention activity (based on
the contrast TO versus RS) was compared between groups,
with session and ROIs (Table 2) as within-subject factors.
We found no significant effects of group (all p values >0.50),
indicating that initial ecstasy use did not affect patterns of
brain activity in the involved network. Then, the modulat-
ing effect of attention on brain activity was compared
between groups, with session and SAT-attention ROIs
(Table 2) as within-subject factors. Again, no significant
differences between groups were found (all p values >0.50).
Associative memory-related brain activity (PMT)
Whole brain analysis Similar to STERN, for PMT, also two
contrasts were examined. First, associative learning-related
activity (AL versus SC) was compared between groups,
with session and ROIs (Table 2) as within-subject factors.
No significant differences between groups were found (all p
values >0.50). Second, brain activity related to recall (RE
versus SC) was compared, also yielding no significant
differences between groups (all p values >0.20). This
indicates that novice ecstasy use did not affect associative
memory activity in the engaged network.
Region of interest analysis Next, analysis was restricted to
four anatomically defined regions, i.e., right and left
hippocampus and right and left parahippocampal gyrus.
Again, two contrasts were examined: AL versus SC and RE
versus SC, also not yielding significant differences between
initial ecstasy users and persistent ecstasy-naive controls (p
values >0.20). In addition, a voxel-by-voxel approach was
used in SPM2. At the FWE-corrected level of p=0.05,
again, no differences were found between novice ecstasy
users and ecstasy-naive controls.
Correlations between ecstasy use and brain activity
Within the group of novice ecstasy users (N=25), we
examined possible associations between two indices of
ecstasy use, cumulative dose (total number of ecstasy
tablets at follow-up) and weeks since last ecstasy use, and
Fig. 5 Regions of interest for
STERN, SAT, and PMT: a Fu-
siform gyrus, b dorsolateral
prefrontal cortex, c superior pa-
rietal cortex, d anterior cingulate
cortex, e inferior frontal cortex, f
auditory cortex, g pre-central
gyrus, h (para)hippocampal re-
gion, i middle occipital gyrus.
The numbers beneath the slices
indicate the MNI z coordinates.
Slices are in radiological orien-
tation (left side is right hemi-
sphere and vice versa)
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outcome variables (performance and brain activity) using
Spearman’s rho correlational analyses. To avoid type I
errors, the level of significance was Bonferroni corrected, i.e.,
using a more stringent p value adjusted for the number of
ROIs. Duration of use was not included as an ecstasy use
variable because the majority of subjects had used ecstasy
only once (N=15, 60%), and thus, scored zero on this
variable.
Task performance
No significant correlations were found between perfor-
mance and cumulative dose or weeks since last use for all
three tasks.
Brain activity
In line with the results on performance, we found no
significant correlations between cumulative dose and
weeks since last ecstasy use and brain activity in any of
the regions of interest for STERN, SAT, and PMT
(Fig. 5).
To examine whether the exclusion of one novice
ecstasy user with a cumulative dose of 20 ecstasy
tablets at follow-up did affect the results, all above-
described statistical analyses were re-run, this time
including this particular subject. The main findings
remained unchanged, as no significant effects of initial
ecstasy use on performance and brain activity for all
three tasks were found. There was only one tentative
effect observed regarding the region of interest analysis
for PMT. Including this subject with a cumulative dose
of 20 tablets yielded a marginally significant interaction
effect [F(1,48)=2.80, p=0.10] between session and group.
Ecstasy users tended to reveal slightly different patterns of
overall brain activity in the four anatomical defined
hippocampal and parahippocampal regions over sessions
in comparison to the controls.
Discussion
The present fMRI study prospectively examined the non-
acute effects of a single or low dose of ecstasy on cognitive
brain function. We assessed task performance and brain
activity patterns during working memory, selective atten-
tion, and associative memory in novice (but at least 2 weeks
abstinent) ecstasy users before and after a period of first
ecstasy use and compared these data with the same baseline
and follow-up measurements of matched controls who did
not use ecstasy during the follow-up period. We did not
find firm evidence for sustained effects of initial ecstasy use
on task performance in the domains of memory and
attention. Also, no effect of incident ecstasy use was found
on brain activity in the brain systems engaged in working
memory, attention, or associative memory.
To date, this is the first prospective fMRI study on
sustained effects of low-dose ecstasy use on cognitive brain
function. Therefore, we can only compare our results with
findings from studies investigating the (mainly acute)
effects of MDMA on human neuropsychological function.
In a recent review, Dumont and Verkes (2006) reported on
all placebo-controlled studies that administered MDMA to
healthy humans. Eleven tests in the attention domain were
evaluated, but none of them had generated any significant
effect. In the executive function domain, the literature
search yielded only one study by Lamers et al. (2003),
which reported no effect of MDMA on visual search,
planning, or retrieval from semantic memory. Surprisingly,
there are no studies about the acute effects of MDMA on
memory, although cross-sectional studies into the long-term
effects of ecstasy on human cognition most consistently
report this domain to be impaired (Verbaten 2003).
We are aware of several limitations of the current study.
For one, although prospective, the study design was
naturalistic and not experimental. Therefore, there is
uncertainty about dosage and purity of ecstasy tablets, and
we had to rely on statements of the subjects themselves.
However, because both novice users and persistent ecstasy-
naive controls were included for follow-up testing from the
initial baseline cohort, we have no reason to question the
truthfulness of their statements. Furthermore, pill testing
confirms that in The Netherlands, more than 95% of the
tablets sold as ecstasy contain MDMA as the sole (91.2%)
or main (4.2%) psychoactive component (The Netherlands
National Drug Monitor, 20043). Another limitation is that
the sample was not randomly selected. Therefore, we
cannot claim it to be statistically representative of the
population of young people on the brink of experimenting
with ecstasy. Yet, we do believe it is sufficiently varied, as
we contacted candidates in many different places and ways.
Moreover, in view of the specific demands of the study (a
fairly demanding research project, including extensive brain
imaging and blood sampling), even an initially random
sample would have almost certainly reached a selective
group in the end. In addition to sample selection, sample
size would preferably have been larger, i.e., more subjects
per group. Although difficult to realize, this would have
further increased statistical power by reducing the chance of
a type II error. Nevertheless, the number of subjects in the
current study is larger than in other fMRI studies on effects
of heavy ecstasy use, in which subjects numbers range
between 6 and 15 ecstasy users and similar numbers of
3 NDM 2004 at http://www.trimbos.nl/.
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controls, only examined once (for a review, see Cowan
2007). Thirdly, the pattern of use, the environmental
circumstances during ecstasy consumption (ambient heat,
dehydration), and the possible interaction with other
substances, for instance alcohol, nicotine, cannabis, co-
caine, or amphetamine (although use of the latter two was
minimal), were not investigated. Therefore, we cannot
exclude the possibility of confounding interactions between
ecstasy and other drugs. More specifically, it has been
suggested that cannabis attenuates the neurotoxic effects of
ecstasy, as cannabis and ecstasy may have opposite effects
on oxidative stress (Parrott et al. 2004). Ecstasy is thought
to cause increased oxidative stress, thereby enhancing the
risk for serotonergic neurotoxicity (Green et al. 2003),
whereas cannabis may act as an antioxidant (Hampson et al.
2000), and therefore, possibly has neuroprotective effects
(Sinor et al. 2000).
Finally, our failure to detect effects of a low dose of
ecstasy on memory and attention and related brain function
may be due to insufficient sensitivity and specificity of the
task paradigms and the fMRI technique that was used. In
this regard, it is important to note that in a previous study
from our own laboratory, we did observe decreased
memory performance and altered patterns of brain activity
in various brain regions involved in associative memory in
(poly-substance) frequent ecstasy users, applying exactly
the same fMRI task paradigms and scanning procedures
(Jager et al. 2007b). FMRI has been shown to be a sensitive
tool in detecting neurocognitive impairments at the very early
stage of multiple sclerosis (Audoin et al. 2006) in patients with
various neuropsychiatric disorders, i.e., schizophrenia and
obsessive-compulsive disorder (Jansma et al. 2004; Johnson
et al. 2006; Van der Wee et al. 2003), and in substance users,
i.e. cannabis users, tobacco smokers, and alcohol users (Bolla
et al. 2005; Jacobsen et al. 2007; Myrick et al. 2004).
In conclusion, the present results provide no firm
evidence for sustained effects of a low dose of ecstasy use
on working memory, selective attention, and associative
memory neither at the behavioral level nor at the neuro-
physiological level. The present findings are relevant for
the development of prevention and harm reduction strate-
gies, i.e., prevention of any drug use might be the preferred
objective, but in many cases, harm reduction might be
the only realistic option. It should be noted, however, that
the result of a single prospective study using just one of the
many available neurotoxicity detection techniques in a
population with a rather narrow dose range is not sufficient
for an evidence-based harm reduction strategy. Therefore,
monitoring of the current sample is worthwhile because the
expected increase in variation in dosage, frequency, and
duration of ecstasy use within this group of novice users
presents us with a unique opportunity for further research.
In addition, more research with fMRI and other neuro-
imaging techniques into the acute and sustained effects of
MDMA on cognitive brain function is needed.
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